MONON BIOVENTURES, LLC

Biotech · Private

Triple-specific CAR-NK cell immunotherapy for glioblastoma

Grants
$2.0M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A Novel Probiotic Platform to Treat Necrotizing Enterocolitis$331,395
Federal grantDepartment of Health and Human Services · Phase II · Soluble, solution-stable phospho-glucagon for hypoglycemic rescue$298,152
Federal grantDepartment of Health and Human Services · Phase II · Soluble, solution-stable phospho-glucagon for hypoglycemic rescue$495,101
Federal grantDepartment of Health and Human Services · Phase II · Soluble, solution-stable phospho-glucagon for hypoglycemic rescue$504,770
Federal grantDepartment of Health and Human Services · Phase I · Off-the-shelf engineered NK cells to treat glioblastoma$399,314
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2091CNS Pharmaceuticals, Inc.—$23M
2092CAYMAN CHEMICAL COMPANY, INCORPORATED——
2093Kairos Pharma, LTD.—$4.2M
2094MONON BIOVENTURES, LLC——
2095Sequor Pharamaceuticals LLC——
2096MIRNA ANALYTICS, LLC——
2097Marathoner Biosciences——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • Modified Glucagon Molecues And Formulations With Oxidation Resistance And Methods And Kits Of Employing The Sameapplication
  • Modified Glucagon Molecules And Formulations With Oxidation Resistance And Methods And Kits Of Employing The Sameapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.